Fairvalue-Calculator Fairvalue-Calculator
EN DE

Kexing Biopharm Co (688136) Fair Value & Analysis

Healthcare · CN · Market cap 3.8B CNY

Price¥18.13
Fair Value¥10.35
Upside-42.9%
Quality95/100
Evidence: High Range ¥7.64 – ¥17.34

Analysis

Kexing Biopharm Co (688136) currently trades at ¥18.13, while our model-based Fair Value estimate is ¥10.35 — implying the stock looks roughly 42.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05 human interferon a1b inhalation solution that is in Phase III clinical trial; GB-K02, an human granulocyte colony-stimulating factor injection in Phase III clinical trial; GB08, an growth hormone that has completed Phase I clinical trial; GB10 for fundus diseases; GB12 for atopic dermatitis; GB18 for cancer cachexia; GB23 for solid tumors; GB24 for inflammatory bowel diseases; and GB25, an tri-specific antibody for colorectal cancer. In addition, the company's produ…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.